Abstract
Acute pulmonary injury is known as acute chest syndrome (ACS) in patients with sickle cell disease (SCD). Secretory phospholipase A2 (sPLA2) was found to predict those at risk for ACS and a trial was designed to determine if red blood cell transfusion can be used to prevent ACS. Patients with an elevated sPLA2 were randomised to either receive a single transfusion or standard care. Five of the eight patients (63%) randomised to standard care developed ACS versus none of the seven patients randomised to the transfusion arm (P = 0.026, Odds ratio = 23.6, 95% confidence interval 1, 557). This study suggests that transfusion may prevent ACS.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Acute Disease
-
Adolescent
-
Anemia, Sickle Cell / complications
-
Anemia, Sickle Cell / enzymology
-
Anemia, Sickle Cell / therapy*
-
Biomarkers / blood
-
Chest Pain / etiology
-
Chest Pain / prevention & control*
-
Child
-
Erythrocyte Transfusion*
-
Female
-
Group II Phospholipases A2
-
Humans
-
Male
-
Phospholipases A / blood*
-
Phospholipases A2
-
Respiration Disorders / etiology
-
Respiration Disorders / prevention & control*
-
Vascular Diseases / complications
-
Vascular Diseases / enzymology
-
Vascular Diseases / therapy
Substances
-
Biomarkers
-
Phospholipases A
-
Group II Phospholipases A2
-
Phospholipases A2